Pancreatic Cancer Pipeline 2016 Market Report of 282 Companies

Aug 02, 2016, 04:00 ET from ReportsnReports

PUNE, India, August 2, 2016 /PRNewswire/ --

ReportnReports.com adds "Pancreatic Cancer - Pipeline Review, H1 2016" market research report providing comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancer and special features on late-stage and discontinued projects.

The report also reviews key players involved in the therapeutic development for Pancreatic Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H1 2016 review of Pancreatic Cancer pipeline with 217 market data tables and 17 figures, spread across 1827 pages is available at http://www.reportsnreports.com/reports/640478-pancreatic-cancer-pipeline-review-h1-2016.html .

Companies discussed in this Pancreatic Cancer Pipeline Review, H1 2016 report include 3-V Biosciences, Inc., 4SC AG, AB Science SA, AbbVie Inc., AbGenomics International, Inc., Ability Pharmaceuticals, S.L., Acetylon Pharmaceuticals, Inc., ACF Pharmaceuticals, LLC, Adamed Sp. z o.o., Adamis Pharmaceuticals Corporation, Aduro BioTech, Inc., Advantagene, Inc., Advaxis, Inc., Agenus, Inc., AGV Discovery, SAS, AIMM Therapeutics B.V., Alchemia Limited, Alethia Biotherapeutics Inc., Allinky Biopharma, Almac Discovery Limited, Altor BioScience Corporation, Ambrx, Inc., American Gene Technologies International Inc., Amgen Inc., Anavex Life Sciences Corp., Andarix Pharmaceuticals, Inc., ANP Technologies, Inc., AntiCancer, Inc., APEIRON Biologics AG, Aphios Corporation, APIM Therapeutics AS, Apogenix GmbH, Aposense Ltd., ArQule, Inc., Array BioPharma Inc., Astellas Pharma Inc., AstraZeneca Plc, ATLAB Pharma SAS, Aurigene Discovery Technologies Limited, AVEO Pharmaceuticals, Inc., Axcentua Pharmaceuticals AB, Azaya Therapeutics, Inc., Basilea Pharmaceutica AG, Bavarian Nordic A/S, Bayer AG, Bellicum Pharmaceuticals, Inc., Berg LLC, BerGenBio AS, Betta Pharmaceuticals Co. Ltd., Bexion Pharmaceuticals, LLC., Biomar Microbial Technologies, Biomunex Pharmaceuticals, Bioncotech Therapeutics S.L., Bionomics Limited, BioNTech AG, BiOrion Technologies B.V., Biotest AG, Biouniversa s.r.l., Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Calithera Biosciences, Inc., Cantargia AB, Cascadian Therapeutics Inc, Cavion LLC, Celgene Corporation, Cellceutix Corporation, Cellectis S.A., Cellular Biomedicine Group, Inc., Celprogen, Inc., Celsion Corporation, Centrose LLC, Ceronco Biosciences, ChemoCentryx, Inc., Chiome Bioscience, Inc., Clovis Oncology, Inc., Coare Biotechnology, Inc., Concordia Healthcare Corp., Confluence Life Sciences, Inc., Cornerstone Pharmaceuticals, Inc., Critical Outcome Technologies Inc., CritiTech, Inc., CrystalGenomics, Inc., CTI BioPharma Corp., Cyclacel Pharmaceuticals, Inc., CytomX Therapeutics, Inc., CytRx Corporation, CyTuVax B.V., Daewoong Pharmaceutical Co., Ltd., DEKK-TEC, Inc., Dicerna Pharmaceuticals, Inc., Diffusion Pharmaceuticals Inc., Eisai Co., Ltd., Eleison Pharmaceuticals LLC, Eli Lilly and Company, Endor Nanotechnologies SL, Ensol Biosciences Inc., Erytech Pharma SA, Esperance Pharmaceuticals, Inc., Etubics Corporation, Exelixis, Inc., F. Hoffmann-La Roche Ltd., FibroGen, Inc., Five Prime Therapeutics, Inc., Forty Seven Inc., Fountain Biopharma Inc., Fujifilm Corporation, Fusion Antibodies Limited, GamaMabs Pharma S.A., Ganymed Pharmaceuticals AG, Geistlich Pharma AG, Genelux Corporation, Genentech, Inc., Genisphere Inc., Genmab A/S, Gilead Sciences, Inc., GlaxoSmithKline Plc, Globeimmune, Inc., GlycoMimetics, Inc., Golden Biotechnology Corp., GW Pharmaceuticals Plc, Halozyme Therapeutics, Inc., HEC Pharm Co., Ltd., Helix BioPharma Corp., iCeutica, Inc., Ignyta, Inc., Immodulon Therapeutics Ltd., Immune Pharmaceuticals Inc., Immune System Key Ltd., Immunomedics, Inc., Immunotope, Inc., Immunovo BV, Immupharma Plc, Incuron, LLC, Incyte Corporation, Inflection Biosciences Limited, Innopharmax Inc., Inovio Pharmaceuticals, Inc., Intica Biomedical, Inc., Inventiva, Io Therapeutics, Inc., Ipsen S.A., Jasco Pharmaceuticals, LLC., Jiangsu Hengrui Medicine Co., Ltd., Johnson & Johnson, Juno Therapeutics Inc., Kadmon Corporation, LLC, Kancera AB, Karcinolys SAS, Karyopharm Therapeutics, Inc., Keystone Nano, Inc., Komipharm International Co., Ltd., Kura Oncology, Inc., Kyowa Hakko Kirin Co., Ltd., Lymphocyte Activation Technologies, S.A., MabVax Therapeutics Holdings, Inc., MacroGenics, Inc., Mateon Therapeutics Inc, MaxiVAX SA, Meabco A/S, Mebiopharm Co., Ltd., MediaPharma s.r.l., Medicenna Therapeutics, Inc., MedImmune, LLC, Medisyn Technologies, Inc., MolMed S.p.A., Momenta Pharmaceuticals, Inc., Monopar Therapeutics LLC, Morphotek, Inc., Multimmune GmbH, Mundipharma International Ltd, NanoCarrier Co., Ltd., NantKwest, Inc., Nascent Biotech, Inc., Natco Pharma Limited, NatureWise Biotech & Medicals Corporation, Nerviano Medical Sciences S.r.l., NewLink Genetics Corporation, NormOxys, Inc., Northwest Biotherapeutics, Inc., Novartis AG, NuCana BioMed Limited, Omeros Corporation, Omnitura Therapeutics Inc., Oncodesign SA, Oncodrone BV, Oncology Research International Limited, Oncolytics Biotech Inc., Oncomatryx Biopharma, S.L., OncoMed Pharmaceuticals, Inc., Oncovir, Inc., Ono Pharmaceutical Co., Ltd., Opsona Therapeutics Limited, Optimum Therapeutics, LLC, Oribase Pharma, Oryx GmbH & Co. KG, Oscotec Inc., Pfizer Inc., Pharma Mar, S.A., Pharma Two B Ltd, PharmAbcine, Inc., Pharmacyclics, Inc., PharmaCyte Biotech, Inc., Pharmedartis GmbH, Phoenix Biotechnology, Inc., Pique Therapeutics, Plexxikon Inc., Polaris Pharmaceuticals, Inc., Precision Biologics, Inc., Prima BioMed Ltd., Provectus Biopharmaceuticals, Inc., Quest PharmaTech Inc. and more.

Order a copy of H1 2016 pancreatic cancer pipeline review report @ http://www.reportsnreports.com/Purchase.aspx?name=640478 .

About Us: 

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com

Connect With Us on:

Facebook:  https://www.facebook.com/ReportsnReports/

LinkedIn:  https://www.linkedin.com/company/reportsnreports

Twitter:  https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds:  http://www.reportsnreports.com/feed/l-latestreports.xml


SOURCE ReportsnReports